New Frontiers in the Treatment and Management of Advanced Breast Cancer: Expert Strategies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from January 1, 2020 to January 1, 2021

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Breast Cancer is the most common cancer found in women, regardless of race or ethnicity. According to the National Cancer Institute, an estimated 231,840 new cases of invasive breast cancer are to be diagnosed in the United States (US) during 2019. The incidence in women in the US is one in eight or about 12%. Death rates have been steadily decreasing over the past 20 years due to new and ever improving treatment options. However, in the later stages of disease, when distant metastases are present, cure becomes less likely and few patients are rendered free of disease. Therapy in the advanced setting then focuses on prolonging life and managing disease-and treatment-related adverse events. Treatment selection must be individualized based upon patient- and tumor-specific factors, as well as the safety and efficacy profile of available agents. Additionally, an emphasis on the combined goals of tumor control, prolonged survival, and maintenance of patient quality of life are paramount. Fortunately for patients with advanced breast cancer, several new agents, including PARP inhibitors have recently become available. They have shown the ability to improve safety and efficacy outcomes, especially in the area of HER2- metastatic breast cancer. Nearly 80% of patients with advanced breast cancer have the HER2-negative subtype and therefore are not candidates for HER2-targeting therapies.

Upon completion of this activity, participants will be able to:

  • Describe the mechanism of action of the different PARP inhibitors and the rationale for PARP inhibition in treating advanced breast cancer

  • Analyze efficacy and safety profiles of new and emerging PARP inhibitors for the treatment of advanced breast cancer

  • Identify patients based on molecular changes and previous therapy that are most likely to benefit from treatments with PARP inhibitors

  • Examine the impact of BRCA1/2 testing on clinical outcomes for patients with advanced breast cancer

  • Assess strategies to mitigate predictable toxicities that have been reported with the use of PARP inhibition strategies

  • Explore the managed care considerations of current and emerging PARP inhibitors by exploring where these agents fit into current advanced breast cancer management paradigm

Faculty: VK Gadi, MD, PhD
Associate Professor of Medicine
Division of Oncology, University of Washington
Associate Member Clinical Research Division
Fred Hutchinson Cancer Research Center
Medical Oncologist, Seattle Cancer Care Alliance


Dr. Gadi owns stock in Sengine Precision Medicine. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue